Probably the game-changing study in the New England Journal, which I was corresponding author on, was STEP 1, which actually launched semaglutide to the world which for the first time caused a result in a 15% weight loss at the end of a year
Bottom line: compounded GLP-1s are not interchangeable with FDA-approved products, and the risk-benefit logic has shifted as branded access pathways improve
What to know about new study showing weight loss drugs can lower cancer risk GLP-1 medications such as Ozempic and Wegovy have exploded in popularity for their weight loss benefits and now new research is showing the medications may help with another condition, cancer
Some research suggests that chronic stress and exposure to stress hormones may play a part in the persistence of obesity
No Pediatric Research Equity Act (PREA) requirement has compelled Novo Nordisk to conduct trials in children aged 6 to 11 for this specific indication, though the company's ClinicalTrials.gov profile lists ongoing pediatric pharmacokinetic studies for semaglutide in younger populations
